Lindahl advised Senzime AB on the deal. Senzime AB (publ) announced a rights issue which was resolved by the board of directors on 23 January 2023 and...
You must be a Standard 1 Year member to access this content.
Lindahl advised Senzime AB on the deal. Senzime AB AB (publ), a company listed on Nasdaq Stockholm that develops and markets CE- and FDA-cleared monitoring systems...
You must be a Standard 1 Year member to access this content.
Lindahl advised Prostatype Genomics on the deal. Prostatype Genomics AB (publ), a company listed on Nasdaq First North Growth Market, develops and markets a prognostic gene...
You must be a Standard 1 Year member to access this content.
Lindahl advised Senzime AB on the deal. Senzime AB announced the company’s list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market. Trading...
You must be a Standard 1 Year member to access this content.
Lindahl assisted Q-linea on the deal. Q-linea AB (publ), a company listed on Nasdaq Stockholm that develops and delivers innovative solutions for the diagnosis of infectious...
You must be a Standard 1 Year member to access this content.
Lindahl assisted Q-linea on the deal. Q-linea AB (publ), a company listed on Nasdaq Stockholm that develops and delivers innovative solutions for the diagnosis of infectious...
You must be a Standard 1 Year member to access this content.
